Philip M. Spanheimer

This study shows that daraxonrasib, a pan-RAS(on) inhibitor, effectively inhibits TNBC cell proliferation and tumor growth, either alone or in combination with a MEK inhibitor.

This study shows vandetanib enhances tamoxifen sensitivity in ER+ breast cancer by reprogramming ER gene regulation and kinase networks, identifying adaptive resistance pathways and response signatures.

The paper identifies non-genetic resistance mechanisms in dedifferentiated liposarcoma to abemaciclib by analyzing cell-cycle regulators in cell lines and patient samples.

This study shows USP7 inhibition disrupts proteostasis and tumor growth in triple negative breast cancer by stabilizing E3 ubiquitin ligases and affecting DNA repair pathways.

This paper uses AI/ML to annotate genomic variants in breast cancer, identifying new actionable mutations and functional consequences beyond known drivers.

The paper shows that ecDNA allows tumors to adapt rapidly by maintaining a spectrum of gene expression levels across cells, rather than relying on clonal expansion.

This paper introduces a multimodal framework to identify drug-responsive subpopulations in triple-negative breast cancer by integrating bulk and single-cell transcriptomics data.

This study identifies regulatory elements that switch from silencers to enhancers in breast cancer cells using single-cell ATAC-seq and RNA-seq data.

This study quantifies kinase protein abundance in human tissues using proteomic mass spectrometry, revealing heterogeneity in breast cancer subtypes and enabling clinical applications.

This study presents single-cell transcriptional and epigenetic profiles of male breast cancer to identify cancer-specific enhancers and their regulatory roles.